Fortress Biotech, Inc. bought ATXI
January 2, 2026 · Form 4 insider transaction
Fortress Biotech, Inc. bought 111,209 shares of Avenue Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
111,209
Price
$0.00
Total value
N/A
InsiderFortress Biotech, Inc.
Role10% owner
SecurityCOMMON STOCK, PAR VALUE $0.0001
Transaction codeA: Grant or award
Transaction dateJanuary 2, 2026
Filing dateJanuary 6, 2026
Shares owned after439,733
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The Reporting Person is entitled to an annual dividend on its Class A Preferred Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. 111,209 shares were granted by the Issuer to the reporting Person for the 2025 annual dividend.